Zacks Rating on Pfizer (PFE)

Pfizer (PFE) : The consensus on Pfizer (PFE) based on 13 analyst recommendation on the company stock is 1.92, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 6 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Pfizer (PFE) stock is expected to deviate a maximum of $5.62 from the average target price of $39.58 for the short term period. 12 Street Experts have initiated coverage on the stock with the most promising target being $54 and the most muted being $33.


Shares of Pfizer Inc. appreciated by 0.86% during the last five trading days but lost 3.8% on a 4-week basis. Pfizer Inc. is up 3.76% in the last 3-month period. Year-to-Date the stock performance stands at 11.7%. Pfizer (NYSE:PFE): stock turned positive on Tuesday. Though the stock opened at $35, the bulls momentum made the stock top out at $35.27 level for the day. The stock recorded a low of $34.91 and closed the trading day at $35.09, in the green by 0.72%. The total traded volume for the day was 16,957,889. The stock had closed at $34.84 in the previous days trading.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.